Difference between revisions of "Lomustine (CCNU)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
(Incorporated Lomustine Dosing Chart)
Tag: visualeditor-switched
Line 32: Line 32:
 
*'''Brand names:''' CeeNu, Gleostine
 
*'''Brand names:''' CeeNu, Gleostine
 
**In 10/2013, Bristol-Myers Squibb discontinued production of their Lomustine brand name, CeeNu.<ref>[http://www.ashp.org/DrugShortages/NotAvailable/bulletin.aspx?id=1023 Discontinued drug bulletin: Lomustine capsules (American Society of Health-System Pharmacists)]</ref>  Lomustine is currently supplied as Gleostine by NextSource Biotechnology LLC.<ref>[http://www.elabs6.com/content/12347425/EP298498RDNW/nextsource5.index.html NextSource Biotechnology Lomustine (CCNU) update]</ref>
 
**In 10/2013, Bristol-Myers Squibb discontinued production of their Lomustine brand name, CeeNu.<ref>[http://www.ashp.org/DrugShortages/NotAvailable/bulletin.aspx?id=1023 Discontinued drug bulletin: Lomustine capsules (American Society of Health-System Pharmacists)]</ref>  Lomustine is currently supplied as Gleostine by NextSource Biotechnology LLC.<ref>[http://www.elabs6.com/content/12347425/EP298498RDNW/nextsource5.index.html NextSource Biotechnology Lomustine (CCNU) update]</ref>
 +
 +
==COG ACNS0331 Lomustine Dosing Nomogram==
 +
 +
===Available Capsule Sizes===
 +
*10 mg
 +
*40 mg
 +
*100 mg
 +
 +
 +
{| class="wikitable" style="width: 40%; text-align:center;"
 +
! style="width: 25%" |Body Surface Area (m<sup>2</sup>)
 +
! style="width: 25%" |Ideal Dose (75 mg/m<sup>2</sup>/day once daily)
 +
! style="width: 25%" |Actual Dose to be Given
 +
|-
 +
|2.0
 +
|150 mg,
 +
|150 mg
 +
|-
 +
|1.9
 +
|143
 +
|140
 +
|-
 +
|1.8
 +
|135
 +
|130
 +
|-
 +
|1.7
 +
|128
 +
|130
 +
|-
 +
|1.6
 +
|120
 +
|120
 +
|-
 +
|1.5
 +
|112
 +
|110
 +
|-
 +
|1.4
 +
|105
 +
|100
 +
|-
 +
|1.3
 +
|98
 +
|100
 +
|-
 +
|1.2
 +
|90
 +
|90
 +
|-
 +
|1.1
 +
|82
 +
|80
 +
|-
 +
|1.0
 +
|75
 +
|80
 +
|-
 +
|0.95
 +
|71
 +
|70
 +
|-
 +
|0.9
 +
|68
 +
|70
 +
|-
 +
|0.85
 +
|64
 +
|60
 +
|-
 +
|0.8
 +
|60
 +
|60
 +
|-
 +
|0.75
 +
|56
 +
|60
 +
|-
 +
|0.7
 +
|53
 +
|50
 +
|-
 +
|0.65
 +
|49
 +
|50
 +
|-
 +
|0.6
 +
|45
 +
|40
 +
|-
 +
|0.55
 +
|41
 +
|40
 +
|-
 +
|0.5
 +
|38
 +
|40
 +
|-
 +
|0.45
 +
|34
 +
|30
 +
|-
 +
|0.4
 +
|30
 +
|30
 +
|-
 +
|0.35
 +
|26
 +
|30
 +
|-
 +
|0.3
 +
|23
 +
|20
 +
|}
  
 
==References==
 
==References==

Revision as of 05:38, 4 February 2022

General information

Class/mechanism: Nitrosourea, alkylates DNA and RNA and may inhibit certain key enzymatic reactions by carbamoylation of amino acids in proteins.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

History of changes in FDA indication

  • 8/4/1976: Initial approval
  • 4/30/2009: (oldest available label at Drugs@FDA) has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in brain tumors—both primary and metastatic, in patients who have already received appropriate surgical and/or radiotherapeutic procedures.
  • 4/30/2009: (oldest available label at Drugs@FDA) has been shown to be useful as a single agent in addition to other treatment modalities, or in established combination therapy with other approved chemotherapeutic agents in Hodgkin’s Disease—secondary therapy in combination with other approved drugs in patients who relapse while being treated with primary therapy, or who fail to respond to primary therapy.

Also known as

  • Generic names: CCNU
  • Brand names: CeeNu, Gleostine
    • In 10/2013, Bristol-Myers Squibb discontinued production of their Lomustine brand name, CeeNu.[5] Lomustine is currently supplied as Gleostine by NextSource Biotechnology LLC.[6]

COG ACNS0331 Lomustine Dosing Nomogram

Available Capsule Sizes

  • 10 mg
  • 40 mg
  • 100 mg


Body Surface Area (m2) Ideal Dose (75 mg/m2/day once daily) Actual Dose to be Given
2.0 150 mg, 150 mg
1.9 143 140
1.8 135 130
1.7 128 130
1.6 120 120
1.5 112 110
1.4 105 100
1.3 98 100
1.2 90 90
1.1 82 80
1.0 75 80
0.95 71 70
0.9 68 70
0.85 64 60
0.8 60 60
0.75 56 60
0.7 53 50
0.65 49 50
0.6 45 40
0.55 41 40
0.5 38 40
0.45 34 30
0.4 30 30
0.35 26 30
0.3 23 20

References

  1. ↑ 1.0 1.1 1.2 Lomustine (Ceenu) package insert
  2. ↑ Lomustine (Ceenu) package insert (locally hosted backup)
  3. ↑ Lomustine (Ceenu) patient drug information (Chemocare)
  4. ↑ Lomustine (Ceenu) patient drug information (UpToDate)
  5. ↑ Discontinued drug bulletin: Lomustine capsules (American Society of Health-System Pharmacists)
  6. ↑ NextSource Biotechnology Lomustine (CCNU) update
Retrieved from "https://hemonc.org/w/index.php?title=Lomustine_(CCNU)&oldid=54393"